Efficacy of and Resistance to Rifaximin-based Quadruple Therapy in *Helicobacter pylori* Eradication

Hyun Soo Kim1,*, Hyuk Yoon1,*, Dong Woo Shin1, Dong Jun Oh1, Mingu Kwon1, Yoon Jin Choi1, Cheol Min Shin1, Young Soo Park1, Nayoung Kim1,2, Dong Ho Lee1,2

Department of Internal Medicine, Seoul National University Bundang Hospital1, Seongnam, Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine2, Seoul, Korea

Received: March 20, 2020 Revised: April 22, 2020 Accepted: April 30, 2020

**Background/Aims:** The treatment options for *Helicobacter pylori* (*H. pylori*) infection are in a state of flux: traditional triple therapies have started to fail, and new treatments are unable to achieve optimal eradication rates. Rifaximin and rifabutin are new antibiotics. The aim of this study was to evaluate the efficacy and safety of adding rifaximin to the standard triple regimen and of a rifabutin-based triple regimen as a rescue therapy for *H. pylori* eradication.

**Materials and Methods:** We enrolled 27 *H. pylori*-positive patients who were treated with a proton pump inhibitor, amoxicillin, clarithromycin, and rifaximin for 14 days. *H. pylori* eradication was assessed by a 13C-urea breath test performed 4 weeks after therapy completion. The efficacy of the therapy was based on intention-to-treat (ITT) and per-protocol (PP) analysis. We also investigated the resistance rate, compliance, and side effects associated with rifaximin therapy. Minimal inhibitory concentrations and resistance to rifabutin were evaluated using the agar dilution method.

**Results:** Of the 27 patients, 22 completed the treatment protocol with 100% compliance; five patients withdrew. The ITT and PP eradication rates for the rifaximin-containing quadruple therapy were 70.4% (19/27) and 86.3% (19/22), respectively. Adverse events were observed in five of 22 patients (22.7%). The resistance rates to rifaximin and rifabutin were 66.7% (2/3) and 0% (0/5), respectively.

**Conclusions:** The findings of this study show the limitations of rifaximin-based quadruple therapy and suggest the benefits of a rifabutin-based rescue regimen in South Korea. (Korean J Helicobacter Up Gastrointest Res 2020;20:218-224)

**Key Words:** Amoxicillin; Clarithromycin; *Helicobacter pylori*; Rifaximin

**INTRODUCTION**

*Helicobacter pylori* (*H. pylori*) is a gram-negative, microaerophilic bacterium that is common worldwide.1,2 For more than 30 years, *H. pylori* has been studied for its role in the development of gastrointestinal diseases, such as chronic gastritis, peptic ulcers, gastric mucosa-associated lymphoid tissue lymphoma, and gastric cancer. It is also categorized as a class I carcinogen by the World Health Organization.3,4 In addition, *H. pylori* is known to be associated with extra-gastrointestinal disorders such as urticaria, idiopathic thrombocytopenic purpura, acne rosacea, migraines, and glaucoma.5-10 Therefore, the success of *H. pylori* eradication is very important for the prevention of disease progress.

The known classic triple regimen, consisting of a proton-pump inhibitor (PPI) with two antibiotics (clarithromycin and amoxicillin/metronidazole), has been considered as the gold standard for the eradication of *H. pylori*.11,12 However, the eradication rate of first-line treatment is only 70% to 85% and is following a decreasing trend due to antibiotic resistance.12-14 In the past years, new antibiotic regimens have been studied to overcome treatment failure. New macrolides, fluoroquinolones, and rifabutin have been used with various eradication rates achieved.15-17 Rifaximin, one of the among the new antibiotics, is a poorly absorbed synthetic rifamycin derivative, which has a wide spectrum of antimicrobial activity against both gram-positive and gram-negative aerobic and anaerobic bacteria.18 As it is poorly absorbed in the gastrointestinal tract, rifaximin has high bioavailability in the gastrointestinal tract. Therefore, it achieves intestinal concentrations that are 250~500 times
higher than the minimal inhibitory concentration (MIC) 90. In in vitro studies, rifaximin was shown to inhibit H. pylori growth (MIC50, 4 μg/mL; MIC90, 8 μg/mL); thus, we believe it is a potential antibiotic for H. pylori eradication. Quesada et al.20 showed that rifaximin was useful against H. pylori strains resistant to clarithromycin21 and suggested that it may be effective in combination with the classic triple therapy or for treatment in patients who have failed previous eradication therapies with clarithromycin. It is known that rifaximin-based 7-day triple therapy (esomeprazole 40 mg o.d., clarithromycin 500 mg b.i.d., rifaximin 400 mg t.i.d.) has a higher compliance rate than the standard triple therapy but a lower eradication rate.22 In addition, Choi et al.23 showed that a rifaximin-based 7-day quadruple regimen (omeprazole 20 mg b.i.d., amoxicillin 1 g b.i.d., levofloxacin 200 mg b.i.d., rifaximin 400 mg b.i.d.) was not inferior to standard triple therapy in eradication rate and had fewer side effects. Therefore, the quadruple therapy, with the addition of rifaximin to the standard triple regimen, is believed to act against clarithromycin-resistant H. pylori strains and increase the eradication rate. In addition, rifabutin-based triple therapy, which includes a rifamycin derivative, has been suggested as a third-line treatment for H. pylori rescue therapy in Europe. However, there have been a few reports, except for retrospective studies, on small samples of patients in Korea.24 Therefore, the aim of this study was to evaluate the efficacy and safety of the addition of rifaximin to the standard triple regimen and the possibility of a rifabutin-based triple regimen as a rescue therapy for the eradication of H. pylori.

**MATERIALS AND METHODS**

1. Patients

We conducted this prospective pilot study between February 2014 and July 2015 at the Seoul National University Bundang Hospital in Korea. We enrolled 27 patients who were naïve to eradication treatment and were infected with H. pylori. H. pylori infection was defined as having at least one of the following: 1) histologic evidence of H. pylori, identified using modified Giemsa staining in the high body greater curvature; 2) a positive rapid urease test (CLO test; Delta West, Bentley, Australia), performed out using a gastric mucosa biopsy from the high body greater curvature; and 3) a positive result for 13C-urea breath test (UBT). We excluded the patients who were below 18 or above 80 years of age, pregnant women, patients with severe pulmonary, renal, or uncompensated liver cirrhosis or any other untreated malignancies. Patients who had taken PPIs, histamine-2 receptor antagonists, or antibiotics within 2 months prior to the trial were also excluded. The study was approved by the Institutional Review Board of the Seoul National University Bundang Hospital (IRB No: B-1308/215-009).

This study was conducted by following the ethical principles for medical research involving human subjects based on the Declaration of Helsinki. Furthermore, it has been approved by the Medical Ethics Committee and aspires to protect the lives, health, privacy, and dignity of research participants.

2. Study design

Patients who met the enrollment and exclusion criteria and signed the informed consent form were administered rifaximin 600 mg b.i.d., amoxicillin 1,000 mg b.i.d., clarithromycin 500 mg b.i.d., and a standard PPI dose (pantoprazole 40 mg, esomeprazole 40 mg, lansoprazole 30 mg, omeprazole 20 mg, rabeprazole 20 mg before meals) b.i.d. as a first-line treatment for H. pylori infection. The treatment duration was 14 days. The patients were educated about the importance of full compliance, warned of the side effects, and provided a contact number of the hospital in case they encountered any problems. Two weeks after the end of the therapy, a post-treatment follow-up visit was scheduled to evaluate compliance and any associated side effects. Compliance was evaluated by direct questioning and by asking the patients to bring all the drugs that had been provided at the beginning of treatment so that they could be accounted for. Four weeks after the treatment was started, H. pylori eradication was then classified as one of the following: 1) no histologic evidence of H. pylori, identi-
fied using modified Giemsa staining in the high body greater curvature; 2) a negative rapid urease test (CLO test; Delta West), measured using a gastric mucosa biopsy from the high body greater curvature; and 3) a negative result for $^{13}$C-UBT.

3. $^{13}$C–UBT

Patients were required to fast for 4 hours before testing. No test meal was provided, and a pre-dose breath sample was obtained. 100 mg of $^{13}$C-urea powder (UBiTKit; Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan) dissolved in 100 mL of water was administered orally, and a second breath sample was collected 20 minutes later. The cut-off value was 2.5‰. The collected samples were analyzed using an isotope ratio mass spectrometer (UBiT-IR300®; Otsuka Pharmaceutical Co. Ltd.). The patients were asked to avoid acid-lowering drugs or antibiotics for 1 week before the UBT.

4. *H. pylori* strains and antibiotic susceptibility testing

Three specimens were used for culture, and the susceptibility of isolated *H. pylori* strains to antibiotics (amoxicillin, clarithromycin, metronidazole, and rifaximin) was determined by using an agar dilution method. *H. pylori* strains previously obtained were cultured at 37°C on brain-heart infusion plates under micro-aerobic conditions (5% O$_2$, 10% CO$_2$, and 85% N$_2$) for 3~5 days. *H. pylori* was identified based on Gram staining, colony morphology, and positive reactions to oxidase, catalase, and urease. We performed MIC tests for the previously mentioned antibiotics using a serial two-fold agar dilution method. The organisms were cultured on Mueller-Hinton agar supplemented with 5% defibrinated sheep’s blood for 48 hours. As we were testing the potential of rifabutin-containing rescue therapy after failure of first-line or second-line treatment, the MIC for rifabutin was also determined. The bacterial suspension, with $1\times10^7$ colony-forming units, was inoculated onto agar plates containing each antibiotic. We identified the MIC after incubation for 72 hours. According to the clinical breakpoints for *H. pylori* proposed by the European Committee on Antimicrobial Susceptibility Testing, the resistance breakpoints for each antibiotic were as follows: 0.12 mg/L for amoxicillin, 0.5 mg/L for clarithromycin, 8 mg/L for metronidazole, 1 mg/L for rifaximin, and 0.25 mg/L for rifabutin.

5. Statistical analysis

The efficacy of *H. pylori* treatment was evaluated by the intention-to-treat (ITT) and per-protocol (PP) methods. ITT analysis compared the treatment groups that were initially allocated. In the case of PP, we excluded patients who were lost to follow-up, had taken less than 85% of the prescribed drugs, or had discontinued treatment due to severe adverse events.

RESULTS

1. Patient population

Twenty-seven consecutive patients (20 men and 7 women, mean age 55.5±13.8 years) were included in this study. As the treatment was not a standard regimen, not many patients agreed to participate in the study. The indications for *H. pylori* eradication treatment were

| Table 1. Baseline Demographics of the Patients |
|-----------------------------------------------|
| **Rifaximin-based quadruple therapy**          |
| Included in ITT analysis                      | 27 |
| Male/female                                   | 20/7 |
| Age (years)                                   | 55.5±13.8 |
| Disease                                       |
| Benign gastric ulcer                          | 8 (29.6) |
| Duodenal ulcer                                | 4 (14.8) |
| Gastric dysplasia or cancer                    | 5 (18.5) |
| Non-ulcer dyspepsia                           | 10 (37.0) |
| Drop out                                      | 5 |
| Noncompliance                                 | 0 (0) |
| Follow-up loss                                | 4 (14.8) |
| Discontinued therapy because of adverse events| 1 (3.7) |

Values are presented as mean±standard deviation or n (%). ITT, intention-to-treat.
as follows: benign gastric ulcer (8, 29.6%), duodenal ulcer (4, 14.8%), gastric dysplasia or cancer (5, 18.5%), and non-ulcer dyspepsia (10, 37%). The characteristics of the study population are summarized in Table 1. Of the 27 patients, 22 completed the treatment protocol; the remaining five patients were excluded from the PP analysis: four patients (14.7%) were lost to follow-up and one patient (3.7%) discontinued therapy owing to severe adverse events. Compliance with the therapy, that is, the percentage of patients who had taken >85% of the drugs prescribed, was 96.3% (n=26) (Fig. 1).

2. Adverse events

We also assessed the safety of the therapy and the associated adverse events. Six patients (22.2%) experienced adverse events during treatment. Most of the adverse events were mild gastrointestinal problems: 7.4% (n=2) experienced nausea or vomiting, 3.7% (n=1) had diarrhea and abdominal pain, and 11.1% (n=3) had dyspepsia. Only one patient complained of severe nausea and discontinued therapy. The adverse events are summarized in Table 2.

3. *H. pylori* eradication rates and resistance rates to antibiotics

The *H. pylori* eradication rates and resistance to antibiotics are described in Table 3 and 4, respectively. The ITT eradication rate was 70.4% (19/27), and the PP eradication rate was 86.3% (19/22). Owing to the various limitations of this study, *H. pylori* culture was successful for only three patients. Antibiotic resistance rates to amoxicillin, clarithromycin, metronidazole, rifaximin, and rifabutin were 0%, 66.7%, 66.7%, 66.7%, and 0%, respectively. Of the three patients who experienced antibiotic resistance testing, two were resistant to rifaximin, but there was no follow-up. Successful eradication occurred in one patient. In addition, none of these three
patients were resistant to rifabutin.

**DISCUSSION**

Although several *H. pylori* eradication regimens have been recently developed, there is no perfect treatment for *H. pylori* eradication, and an eradication rate of 100% has not been reported. 26 Although there are a variety of factors that account for the inefficiency of the eradication regimens, it is most likely due to the adverse effects caused by the antibiotics, resulting in poor compliance to treatment, and increased antibiotic resistance to clarithromycin and metronidazole. 27,28 Rifamycin derivatives (rifampicin, rifabutin, and rifaximin) exert antibacterial activity against *H. pylori*. Rifabutin has been used as a rescue therapy after failed eradication therapy. Rifaximin is a relatively new alternative antibiotic, belonging to the same family as rifabutin; it is poorly absorbed in the gastrointestinal tract, and does not cause adverse effects. 29,30 Owing to these pharmacokinetic and pharmacodynamic characteristics, the activity of rifaximin against *H. pylori* was studied in vitro and in vivo. In an *in vitro* study, 43 strains of *H. pylori* were examined to determine MICs using four antimicrobial compounds: rifaximin, rifampicin, amoxicillin, and colloidal bismuth subcitrate. 31 The activity of rifaximin was intermediate, between that of amoxicillin, one of the most active agents against *H. pylori*, and colloidal bismuth subcitrate, which has moderate activity. 32 Interestingly, the MIC value of rifaximin is hardly affected by lowering the pH from 7.2 to 6. No strain exhibited primary resistance to rifaximin. 31 So far, several studies have assessed the efficacy of rifaximin, focusing on dual, triple, and quadruple regimens. As rifaximin is known to be effective against *H. pylori* strains resistant to clarithromycin, it was supposed that this antibiotic could be associated with this drug in vitro. 21,33 Several studies evaluating the efficacy of rifaximin have been performed, mostly with dual or triple therapies. Dual regimens combining omeprazole or clarithromycin with metronidazole or bismuth salts have shown eradication rates between 40% and 70%. 34,35 Triple regimens combining rifaximin suspension (600 mg t.i.d.), omeprazole (40 mg o.d.), and amoxicillin (1 g b.i.d.) for 2 weeks achieved eradication rates of 60%. Gasbarrini et al. 22 chose the triple therapy combining rifaximin (400 mg t.i.d.), esomeprazole (40 mg o.d.), and clarithromycin (500 mg b.i.d.) for 7 days and obtained an eradication rate of 58%. 26 Two papers have been published about rifaximin-based quadruple therapies. One (omeprazole 20 mg o.d., amoxicillin 1 g b.i.d., rifaximin 400 mg b.i.d., and levofloxacin 200 mg b.i.d. for 7 days) describes a double-blind, randomized, controlled trial that obtained an eradication rate of 80%. 21 The other included a quadruple therapy with rifaximin (rifaximin 400 mg t.i.d., clarithromycin 500 mg t.i.d., amoxicillin 1 g b.i.d., and omeprazole 20 mg for 10 days) with a PP eradication rate of only 61%. In our study, we combined rifaximin with clarithromycin, amoxicillin, and PPI, and found a PP eradication rate of 86.3%, slightly below the established efficacy consensus threshold (90%). This study has demonstrated the considerable efficacy of the rifaximin-based quadruple therapy and its remarkable safety. However, this regimen cannot be recognized as one of the standard eradication regimens. Because our study employed only three resistance tests, it is difficult to draw firm conclusions. Although it is true that clarithromycin has high resistance potential, the high resistance rate observed in our study was thought to be because of the small number of samples tested for resistance. However, resistance to rifaximin is 66.6%; therefore, it is likely that rifaximin resistance is quite high in Korea. Unlike rifaximin, the resistance rate to rifabutin was 0%, and it can be used in the rescue therapy for *H. pylori*. The reason rifabutin is useful in *H. pylori* treatment is that rifabutin has no cross-resistance with clarithromycin and is not a widely used antibiotic. Therefore, it is considered that *H. pylori* has a low resistance to rifabutin. 37 The results of our study show the practical limitations of first-line rifaximin-based quadruple therapy, and further research on third-line rifabutin-based regimens is needed.

In conclusion, the results of this study have described the limitations of current rifaximin-based quadruple therapy and the potential for a rifabutin-based rescue regimen in Korea. Further studies exploring different
drug combinations, dosing, and durations of therapy are necessary to verify the efficacy of rifaximin and rifabutin in the treatment of *H. pylori* infection.

**CONFLICT OF INTEREST**

No potential conflict of interest relevant to this article was reported.

**ORCID**

Hyun Soo Kim https://orcid.org/0000-0001-7805-4429

Hyuk Yoon https://orcid.org/0000-0002-2557-0549

Dong Jun Oh https://orcid.org/0000-0002-7317-3469

Mingu Kwon https://orcid.org/0000-0002-6516-952X

Yoon Jin Choi https://orcid.org/0000-0002-1922-9588

Cheol Min Shin https://orcid.org/0000-0003-2265-9845

Young Soo Park https://orcid.org/0000-0003-1893-7726

Nayoung Kim https://orcid.org/0000-0002-9397-0406

Dong Ho Lee https://orcid.org/0000-0002-6376-410X

**REFERENCES**

1. Qadri Q, Rasool R, Gulzar GM, Naqash S, Shah ZA. *H. pylori* infection, inflammation and gastric cancer. J Gastrointest Cancer 2014;45:126–132.

2. Yari F, Abiri R, Aryan E, Ahmadi Jouybari T, Navabi J, Alvandi A. Loop-mediated isothermal amplification as a fast noninvasive method of *Helicobacter pylori* diagnosis. J Clin Lab Anal 2016;30:464–470.

3. Du LJ, Chen BR, Kim JJ, Kim S, Shen JH, Dai N. *Helicobacter pylori* infection and extragastric diseases—other *Helicobacter* spp. Helicobacter 2004;9 Suppl 1:57–66.

4. Vázquez Romero M, Bermejo San José F, Boixeda de Miquel D, et al. Chronic urticaria and *Helicobacter pylori*. Med Clin (Barc) 2004;122:573–575.

5. Franchini M, Veneri D. *Helicobacter pylori* infection and immune thrombocytopenic purpura: an update. Helicobacter 2004;9:342–346.

6. Candelli M, Carloni E, Nista EC, et al. *Helicobacter pylori* eradication and acne rosacea resolution: cause-effect or coincidence? Dig Liver Dis 2004;36:163–169.

7. Gabrielli M, Fiore G, Candelli M, et al. Re: "Chronic *Helicobacter pylori* infection and migraine: a case-control study" (Piniessi L, Savi L, Pellicano R, et al. Headache. 2000;40:836–839). Headache 2002;42:236–237; author reply 235–236.

8. Gasbarrini A, Gasbarrini G, Chisholm SA. Helicobacter *pylori* cytotoxic type I CagA-positive strains and migraine with aura. Cephalalgia 2000;20:561–565.

9. Malfertheiner P, Megraud F, O’Morain C, et al. Current concepts in the management of *Helicobacter pylori* infection: the Maastricht III Consensus Report. Gut 2007;56:772–781.

10. Chey WD, Wong BC; Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of *Helicobacter pylori* infection. Am J Gastroenterol 2007;102:1808–1825.

11. Kim JM, Kim JS, Jung HC, Kim N, Kim YJ, Song IS. Distribution of antibiotic MICs for *Helicobacter pylori* strains over a 16-year period in patients from Seoul, South Korea. Antimicrob Agents Chemother 2004;48:4843–4847.

12. Kim N, Kim JM, Kim CH, et al. Institutional difference of antibiotic resistance of *Helicobacter pylori* strains in Korea. J Clin Gastroenterol 2006;40:683–687.

13. Perri F, Festa V, Clemente R, Quitadamo M, Andritelli A. Rifabutin-based ‘rescue therapy’ for *Helicobacter pylori* infected patients after failure of standard regimens. Aliment Pharmacol Ther 2000;14:311–316.

14. Canducci F, Ojetti V, Pola P, Gasbarrini G, Gasbarrini A. Rifabutin-based *Helicobacter pylori* eradication ‘rescue therapy’. Aliment Pharmacol Ther 2001;15:143–151.

15. Scarpignato C. Rifaximin: a poorly absorbed antibiotic. Pharmacology and clinical use. Basel: Karger Medical and Scientific Publishers, 2005.

16. Jiang ZD, DuPont HL. Rifaximin in vitro and in vivo antibacterial activity—a review. Chemotherapy 2005;51 Suppl 1:67–72.

17. Queseda M, Sanfelüí I, Junquera F, Segura F, Calvet X. Evaluation of *Helicobacter pylori* susceptibility to rifaximin. Gastroenterol Hepatol 2004;27:393–396.

18. Scarpignato C, Pelosi P. Bismuth compounds for eradication of *Helicobacter pylori*: pharmacology and safety. In: Scarpignato C, Bianchi Porro G, eds. Clinical pharmacology and therapy of *Helicobacter pylori* infection. Vol. 11. Basel: Karger Publishers, 1999:87–127.

19. Canducci F, Ojetti V. Bismuth compounds for eradication of *Helicobacter pylori*: pharmacology and safety. In: Scarpignato C, Bianchi Porro G, eds. Clinical pharmacology and therapy of *Helicobacter pylori* infection. Vol. 11. Basel: Karger Publishers, 1999:87–127.

20. Gasbarrini A, Lauritano EC, Nista EC, et al. Rifaximin-based regimens for eradication of *Helicobacter pylori*: a pilot study. Dig Dis 2006;24:195–200.

21. Choi KH, Chung WC, Lee KM, et al. Efficacy of levofloxacin and rifaximin based quadruple therapy in *Helicobacter pylori*-associated gastroduodenal disease: a double-blind, randomized controlled trial. J Korean Med Sci 2011;26:785–790.
regimen as the rescue treatment for *Helicobacter pylori*. Helicobacter 2014;19:455-461.

25. Zhang YX, Zhou LJ, Song ZQ, Zhang JZ, He LH, Ding Y. Primary antibiotic resistance of *Helicobacter pylori* strains isolated from patients with dyspeptic symptoms in Beijing: a prospective serial study. World J Gastroenterol 2015;21:2786-2792.

26. Nizhevich AA, Shcherbakov PL, Akhmadeeva ÉN, Khasanov RSh. Rifaximin in combined treatment of the *Helicobacter pylori* infection in childhood. Eksp Klin Gastroenterol 2011:85-87.

27. Gisbert JP, Calvet X. Review article: the effectiveness of standard triple therapy for *Helicobacter pylori* has not changed over the last decade, but it is not good enough. Aliment Pharmacol Ther 2011;34:1255-1268.

28. Houben MH, van de Beek D, Hensen EF, de Craen AJ, Rauws EA, Tytgat GN. A systematic review of *Helicobacter pylori* eradication therapy—the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther 1999;13:1047-1055.

29. Scarpignato C, Pelosini I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy 2005;51 Suppl 1:36-66.

30. Baker DE. Rifaximin: a nonabsorbed oral antibiotic. Rev Gastroenterol Disord 2005;5:19-30.

31. Mégraud F, Bouffant F, Camou Juncas C. In vitro activity of rifaximin against *Helicobacter pylori*. Eur J Clin Microbiol Infect Dis 1994;13:184-186.

32. De Giorgio R, Stanghellini V, Barbara G, Guerrini S, Ferriani A, Corinaldesi R. Rifaximin and *Helicobacter pylori* eradication. Eur Rev Med Pharmacol Sci 1997;1:105-110.

33. Lauritano EC, Gabrielli M, Lupascu A, et al. Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2005;22:31-35.

34. Dell’Anna A, Azzarone P, Ferrieri A. A randomized openly comparative study between rifaximin suspension versus rifaximin pills for the eradication of *Helicobacter pylori*. Eur Rev Med Pharmacol Sci 1999;3:105-110.

35. Pretolani S, Bonvicini F, Brocci E, et al. Effect of rifaximin, a new non-absorbed antibiotic, in the treatment of *Helicobacter pylori* infection. Acta Gastroenterol Belg 1993;56:144A.

36. Vaira D, Menegatti M, Miglioli M, et al. Rifaximin suspension for the eradication of *Helicobacter pylori*. Curr Ther Res 1997;58:300-308.

37. Mégraud F, Lamouliatte H. Review article: the treatment of refractory *Helicobacter pylori* infection. Aliment Pharmacol Ther 2003;17:1333-1343.